{
  "documentMetadata": {
    "title": "Herpes simplex, Genital",
    "lastUpdated": "2021-11-22",
    "sourceFile": "Herpes simplex, Genital.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 2,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Genital herpes simplex infection: Initial and recurrent episodes.",
        "Review: N Engl J Med 2016;375: 666; 2021 CDC STI Guidelines MMWR Recomm Rep 70 (RR-4):1 2021",
        "Pregnancy considerations:",
        "Acyclovir is safe even in the first trimester.",
        "No proof that Acyclovir at delivery reduces risk/severity of neonatal herpes.",
        "In contrast, C-section in women with active lesions reduces risk of transmission. See Obstet Gynecol 106:845, 2005.",
        "Increased risk of dissemination to include severe, and even fatal, hepatitis: N Engl J Med 370: 2211, 2014.",
        "For recalcitrant pseudotumoral anogenital herpes, type 2, in HIV patients, see Comment."
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Herpes simplex virus (HSV) (Types 1, 2)"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Primary Regimens"
    },
    {
      "type": "list",
      "items": [
        "Primary (initial episode)",
        "Acyclovir 400 mg po tid x 7-10 days",
        "Valacyclovir 1000 mg po bid x 7-10 days",
        "Famciclovir 250 mg po tid x 7-10 days",
        "Subsequent recurrent episodes",
        "Immunocompetent",
        "Acyclovir 800 mg po tid x 2 days or 400 mg po tid x 5 days",
        "Famciclovir 1000 mg bid x 1 day or 125 mg po bid x 5 days",
        "Valacyclovir 500 mg po bid x 3 days or 1 gm po once daily x 5 days",
        "Immunocompromised, HIV",
        "Acyclovir 400 mg po tid x 5-10 days",
        "Famciclovir 500 mg po bid x 5-10 days",
        "Valacyclovir 1 gm po bid x 5-10 days"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Alternative Regimens"
    },
    {
      "type": "list",
      "items": [
        "For severe cases only: Acyclovir 5 mg/kg IV q8h x 5-7 days",
        "Acyclovir-resistant HSV: Foscarnet 80 -120 mg/kg/day in 2 - 3 divided doses x 7 days OR",
        "Cidofovir 5 mg/kg IV q wk until clinical response",
        "Chronic suppression (daily)",
        "Immunocompetent",
        "Acyclovir 400 mg po bid",
        "Famciclovir 250 mg po bid",
        "Valacyclovir 1 gm po q24h",
        "Patients with < 9 recurrences per year could use 500 mg po q24h and then 1 gm po q24h if breakthrough at 500 mg.",
        "In Cochrane review, above regimens equally efficacious. Number of recurrences reduced by 40-60% (Cochrane Database Syst Rev 8:CD009036, 2014)",
        "Immunocompromised, HIV",
        "Acyclovir 400-800 mg po bid or tid",
        "Famciclovir 500 mg po bid",
        "Valacyclovir 500 mg po bid"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "Acyclovir reduced by 2 days time to resolution of signs and symptoms, reduced by 4 days time to healing of lesions, reduced by 7 days duration of viral shedding. Does not prevent recurrences once discontinued.",
        "Valacyclovir is an ester of acyclovir, which is well absorbed, bioavailability 3-5 > acyclovir.",
        "Famciclovir is metabolized to penciclovir, which is active component. Side effects and activity similar to acyclovir. Famciclovir 250 mg po tid equal to Acyclovir 200 mg 5x/day.",
        "Suppressive therapy reduces the frequency of genital herpes recurrences by 70-80% among patients who have frequent recurrences (i.e., >6 recurrences per year) and many report no symptomatic outbreaks.",
        "References: 2021 CDC STI Guidelines MMWR Recomm Rep 70 (RR-4):1 2021 and N Engl J Med 2016;375, 666",
        "Atypical hypertrophic, ulcerative or pseudotumor forms reported in HIV patients",
        "CD4 count maybe normal and HIV viral \"load\" undetectable",
        "Frequent failure to respond to acyclovir",
        "In one report only 2 of 10 patients responded to acyclovir/valacyclovir, foscarnet, or cidofovir; 5 of 10 responded to imiquimod and/or thalidomide",
        "See Clin Infect Dis 57:1648, 2013."
      ]
    }
  ]
}